3-(2'-chloro-[1,1'-biphenyl]-4-yl)propanoic acid | 39802-80-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2'-chloro-[1,1'-biphenyl]-4-yl)propanoic acid
• 英文别名: 3-(4-(2-chlorophenyl)phenyl)propanoic acid；β-(2'-chloro-4-biphenylyl)propionic acid；beta-(2'-Chloro-4-biphenylyl)propionic acid；3-[4-(2-chlorophenyl)phenyl]propanoic acid
• CAS: 39802-80-7
• 化学式: C₁₅H₁₃ClO₂
• 分子量: 260.72
• InChiKey: WROMQWDAARAOMP-UHFFFAOYSA-N

物化性质

• 沸点：
  410.8±33.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2'-chloro-[1,1'-biphenyl]-4-yl)propanoic acid 在 4-二甲氨基吡啶 、 水 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 96.0h， 生成 2-(3-(4-(2-chlorophenyl)phenyl)propanamido)benzoic acid
  参考文献：
  名称：

  Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists

  摘要：

  Structure-affinity relationship (SAR) and structure-kinetics relationship (SKR) studies were combined to investigate a series of biphenyl anthranilic acid agonists for the HCA(2) receptor. In total, 27 compounds were synthesized and twelve of them showed higher affinity than nicotinic acid. Two compounds, 6g (IC50 = 75 nM) and 6z (IC50 = 108 nM) showed a longer residence time profile compared to nicotinic acid, exemplified by their kinetic rate index (KRI) values of 1.31 and 1.23, respectively. The SAR study resulted in the novel 2-F, 4-OH derivative (6x) with an IC50 value of 23 nM as the highest affinity HCA(2) agonist of the biphenyl series, although it showed a similar residence time as nicotinic acid. The SAR and SKR data suggest that an early compound selection based on binding kinetics is a promising addition to the lead optimization process. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.02.018
• 作为产物：
  描述：

  3-(4-碘苯基)丙酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 3-(2'-chloro-[1,1'-biphenyl]-4-yl)propanoic acid
  参考文献：
  名称：

  Synthesis and evaluation of ( E )-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists

  摘要：

  Novel series of compounds consisting of 2-amidocyclohex-1-ene carboxylate and phenyl parts which are connected by enyne (compounds 2a-f), but-1-yne (compounds 4a-j), and phenylethylene (compounds 5a-f) linkers as HCA2 full agonists were designed and their functional activity using cAMP assay and binding affinity using radioligand (H-3-niacin) binding assay were evaluated. In general, compounds of all three series exhibit similar HCA2 binding and activation profile. However, the activity is strongly dependent on the substituent at the aromatic part of the structure. Among the structures evaluated, the highest affinity and potency in all series were exhibited by compounds containing 4-hydroxy and/or 2-chloro or 2-fluoro substituents. The most active compounds in the enyne and but-1-yne series in the cAMP assay are 2-fluoro, 4-hydroxy and 2-chloro, 4-hydroxy phenyl derivatives 2f, 4f, and 4g showing potency similar to the previously described 4-hydroxy-biphenyl analogue 5c. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.06.028

文献信息

• Synthesis, biological evaluation, and structure activity relationship (SAR) study of pyrrolidine amide derivatives as <i>N</i>-acylethanolamine acid amidase (NAAA) inhibitors
  作者：Pan Zhou、Lei Xiang、Dongsheng Zhao、Jie Ren、Yan Qiu、Yuhang Li

  DOI：10.1039/c8md00432c

  日期：——

  N-Acylethanolamine acid amidase (NAAA) is one of the key enzymes involved in the degradation of fatty acid ethanolamides (FAEs), especially for palmitoylethanolamide (PEA). Pharmacological blockage of NAAA restores PEA levels, providing therapeutic benefits in the management of inflammation and pain. In the current work, we showed the structure-activity relationship (SAR) studies for pyrrolidine amide

  N-酰基乙醇胺酸酰胺酶（NAAA）是参与脂肪酸乙醇酰胺（FAE）降解的关键酶之一，尤其是对于棕榈酰乙醇酰胺（PEA）而言。NAAA的药理学阻断作用可恢复PEA水平，从而在炎症和疼痛的治疗中提供治疗益处。在当前的工作中，我们显示了吡咯烷酰胺衍生物作为NAAA抑制剂的结构-活性关系（SAR）研究。检查了吡咯烷酰胺的末端苯基的一系列芳族取代基或取代基。SAR数据表明，较小的亲脂性3-苯基取代基对于最佳效用是优选的。构象柔性的接头增加了吡咯烷酰胺衍生物的抑制能力，但降低了其对脂肪酸酰胺水解酶（FAAH）的选择性。构象上受限的接头没有增强抑制剂对NAAA的效力，但是改善了对FAAH的选择性。开发了几种低微摩尔有效的NAAA抑制剂，其中包括带有刚性4-苯基肉桂酰基的4g。透析和动力学分析表明4g通过竞争和可逆的机制抑制NAAA。此外，4g在脂多糖（LPS）诱导的急性肺损伤（ALI）模型中显示出较高的抗
• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：UNIV SYDDANSK

  公开号：WO2010012650A1

  公开（公告）日：2010-02-04

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type Il diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一种新型化合物，能够调节G蛋白偶联受体GPR40，包括该化合物的组合物和使用方法，用于控制体内胰岛素水平，治疗II型糖尿病、高血压、酮症、肥胖症、葡萄糖不耐受症和与异常高或低血浆脂蛋白、甘油三酯或葡萄糖水平相关的相关疾病。
• Phenyl butyric acids and derivatives thereof
  申请人：William H. Rorer, Inc.

  公开号：US03966801A1

  公开（公告）日：1976-06-29

  Novel substituted phenyl butyric acids and their derivatives are described. Therapeutic compositions and method of treatment of inflammation is also disclosed.

  本文描述了一种新型的取代苯丁酸及其衍生物。还公开了治疗炎症的治疗组合物和方法。
• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES
  申请人：Ulven Trond

  公开号：US20110152315A1

  公开（公告）日：2011-06-23

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一种新的化合物，能够调节G蛋白偶联受体GPR40，包括该化合物的组合物以及使用它们的方法，用于控制体内胰岛素水平和治疗诸如2型糖尿病、高血压、酮症酸中毒、肥胖症、葡萄糖耐受性不良以及与异常高或低血浆脂蛋白、甘油三酯或葡萄糖水平有关的相关疾病。
• US3966801A
  申请人：——

  公开号：US3966801A

  公开（公告）日：1976-06-29